Research programme: Staphylococcus epidermidis monoclonal antibodies - Inhibitex

Drug Profile

Research programme: Staphylococcus epidermidis monoclonal antibodies - Inhibitex

Alternative Names: SdrG; SdrG mAb; SE-mAb

Latest Information Update: 13 Jul 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inhibitex
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 13 Jul 2009 Discontinued - Preclinical for Staphylococcal infections in USA (Parenteral)
  • 21 Aug 2007 Preclinical development is ongoing
  • 21 Aug 2007 This research programme is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top